• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, January 27, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Lindquist investigator research on mucormycosis, the deadly ‘black fungus’

Bioengineer by Bioengineer
May 14, 2021
in Cancer
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Start-up Vitalex Biosciences is manufacturing humanized monoclonal antibodies that would stem the spread of this fatal disease

IMAGE

Credit: The Lundquist Institute

LOS ANGELES (May 13, 2021) — The Lundquist Institute today announced that one of its spinoff start-up companies, Vitalex Biosciences, founded by researcher Dr. Ashraf Ibrahim, is producing an antibody that stems the spread of mucormycosis, a deadly fungal infection with an overall mortality rate of 50% and higher. Mucormycosis is an emerging infection caused by exposure to mucor, a mold commonly found in soil, plants, manure, and decaying fruits and vegetables. It affects the sinuses, the brain and the lungs and is life-threatening in diabetic or severely immunocompromised individuals, such as cancer patients. In addition to the >50% death rates, extremely disfiguring surgery is often needed to remove necrotic tissues.

“Once the immune system is compromised such as in diabetic, and cancer patients who lack white blood cells due to chemotherapy, or patients receiving corticosteroid therapy as for example in transplantation patients to prevent organ rejection,” says Dr. Ibrahim, “the fungus turns deadly with the ability to rapidly invade tissues and cause severe necrosis which is why it is called the black fungus. In the era of COVID-19, steroids treatment such as dexamethasone have emerged as a useful treatment to lower the deadly over exuberant inflammatory response. However, reducing the inflammatory response affects the ability to fight opportunistic infections such as mucormycosis. Reports have emerged of fungal infections including mucormycosis in these patients.”

Ibrahim further explains, “Specifically, the use of corticosteroids in diabetic patients with poorly controlled diabetes represents a perfect storm for a disease like mucormycosis because poorly controlled blood sugar and steroid treatment are known to predispose patients to mucormycosis. For example, what used to be a 6-case disease over one year at a hospital in Mumbai, is now 24 cases in two months among COVID-19 patients.”

(Recent news reports have provided more details on how the fungus is particularly attacking COVID patients in India.)

“Our laboratory has discovered a molecule that allows the fungus to invade human cells,” says Dr. Ibrahim. “Our preclinical studies indicated that a mouse antibody targeting this molecule is highly protective against mucormycosis especially when given combined with antifungal drugs. A humanized version of this antibody is currently in manufacturing by Vitalex Biosciences. It is hoped that this antibody will improve the outcome of the disease and save lives from mucormycosis including those with COVID-19.”

###

Media Contact for The Lundquist Institute:

Max Benavidez [email protected] 310-200-2682

Financial Disclosure

Funding from a Small Business Innovation Research (SBIR), and R01 mechanisms from the National Institute of Allergy and Infectious Diseases (NIAID) was provided to Vitalex Biosciences and The Lundquist Institute, respectively, to sponsor Dr. Ibrahim’s work on mucormycosis.

About the Lundquist Institute: Research with Reach

The Lundquist Institute is an engine of innovation with a global reach and a 69-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, the Lundquist Institute serves as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous, and often fatal orphan diseases.

Media Contact
MAX BENAVIDEZ
[email protected]

Tags: AIDS/HIVBacteriologycancerCritical Care/Emergency MedicineDeath/DyingDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesMedicine/HealthPublic Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Figure 1

Afternoon chemotherapy proved to deliver more desirable results for female lymphoma patients

January 27, 2023
First co-authors

Antibodies against coronavirus coldspots discovered

January 26, 2023

Oncotarget | Intraventricular immunovirotherapy; a translational step forward

January 26, 2023

Cancer-selective supramolecular chemotherapy by disassembly-assembly approach

January 26, 2023
Please login to join discussion

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    63 shares
    Share 25 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    57 shares
    Share 23 Tweet 14
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Discovery of new form of carbon, called long-range ordered porous carbon (LOPC)

From AI software to surgical robots

Afternoon chemotherapy proved to deliver more desirable results for female lymphoma patients

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In